Science Corp isn't diving into brain surgery just for the thrill. The company plans to place a tiny sensor on a human brain during an already scheduled operation. The 520-electrode chip, no bigger than a pea, will rest on the brain's surface, recording activity without digging deep. This isn't a sci
Two biotech firms are trying to cash in on investor excitement around obesity drugs and disease-detecting technology. One company wants $533 million to develop weight-loss treatments, while another seeks $159 million to expand its diagnostic tools. Both plan to sell shares to the public soon, hoping
A Chinese biotech company in Suzhou has given an American firm the worldwide rights to create and sell six new RNA medicines aimed at a serious liver condition. The deal brings an upfront cash payment of $60 million and could grow to nearly $4. 5 billion if the medicines reach several key develop
Scientists have been working on making a special enzyme better at producing a form of vitamin D. This enzyme is a mix of different parts, like a custom-made tool. The usual way to improve such enzymes is to tweak small parts here and there. But this time, the team took a bigger picture approach. Th
ViroMissile, Inc. has welcomed Michael G. Wood as their new Chief Business Officer. This move is big news for the company, which is working on a new way to fight cancer using viruses. Wood's job will be to help the company grow, find money for projects, and make important deals. Wood has a lot of e
January 14, 2026, was a big day for tech funding. Investors put a lot of money into AI, robotics, and cybersecurity. Skild AI got $1. 4 billion to build a "brain" for robots. This brain can control different types of robots, like humanoids and drones. The company wants to make robots smarter and mor
Medpace, a notable player in the biotech industry, has been making waves with its recent performance. The company's stock has been under the microscope, showing signs of a potential early buy point. This comes at a time when biotech funding is seeing a much-needed improvement, which could be a game-
A prominent figure in the biotech world has raised a red flag. Noubar Afeyan, a well-known investor, has expressed concerns about a growing resistance to science in the United States. He believes this trend could have serious consequences. In a recent letter to investors, Afeyan warned that rejecti
The biotech and life sciences industry is at a crossroads. After a few tough years, there's a glimmer of hope for recovery. The need for new medical treatments is huge. There are many diseases that still don't have effective treatments. The pharmaceutical industry is also under pressure. Many of the
On January 8, 2026, investors poured money into startups working on AI, healthcare, and other cutting-edge tech. The big winners included xAI, which raised a whopping $20 billion to build advanced AI systems, and Cyera, which got $400 million to help companies keep their AI secure. In the world of
